Daewoong Pharmaceutical has opened an advanced biologics manufacturing site at Yonsei University's International Campus in Songdo, Incheon, to support clinical research into stem cell and immune cell products. The facility includes global-standard sterile manufacturing and quality control systems, with legal approval procedures for manufacturing and processing advanced biologics planned for completion this year before full operations begin. The site is designed to move more than a decade of advanced bio research into clinical stages involving actual patients and to provide stable production capacity for clinical materials. Daewoong plans to connect the facility with its Yongin Bio Center and overseas bases including Indonesia, while expanding cooperation with universities, research institutes and medical institutions across the Songdo bio cluster. The company aims to build an advanced regenerative medicine ecosystem linking research, clinical work and production through industry, academic, research and hospital collaboration.